This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Solid fiscal Q4 for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
Stock Market News For Nov 14, 2018
by Zacks Equity Research
Wall Street ended mostly lower on Tuesday as crude oil prices continued their downward journey
BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems
by Zacks Equity Research
BD's (BDX) diagnostics portfolio boasts tests used for rapid susceptibility testing.
Top Research Reports for Berkshire Hathaway, AbbVie & Booking Holdings
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), AbbVie (ABBV) and Booking Holdings (BKNG).
Becton, Dickinson (BDX) Q4 Earnings Beat, FY19 View Strong
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4; fiscal 2019 guidance solid.
Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.34% and 1.01%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Becton, Dickinson (BDX)
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) likely to gain from its Kidney Care wing. However, DaVita RX and GranuFlo units are likely to disappoint.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) likely to gain from strong segmental contributions in fiscal Q4.
Will Flagship Impella Drive Abiomed's (ABMD) Q2 Earnings?
by Zacks Equity Research
Abiomed (ABMD) likely to gain from flagship Impella in Q2; a competitive industry is a headwind.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
by Zacks Equity Research
Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.
What's in Store for Weight Watchers' (WTW) Q3 Earnings?
by Zacks Equity Research
Weight Watchers (WTW) likely to see soft segmental revenues in Q3; EPS guidance raised.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
Top Analyst Reports for Becton, Dickinson, Occidental Petroleum & Phillips 66
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Becton, Dickinson (BDX), Occidental Petroleum (OXY) and Phillips 66 (PSX).
Stock Market News For Sep 10, 2018
by Zacks Equity Research
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.